Summary of Alto Neuroscience Conference Call Company Overview - **Company**: Alto Neuroscience (NYSE: ANRO) - **Focus**: Development of treatments for treatment-resistant depression (TRD) and cognitive impairment in schizophrenia Key Points on ALTO-207 and TRD - **ALTO-207**: A significant asset for Alto Neuroscience, focusing on TRD, which represents a massive unmet medical need [2][3] - **Dopamine Modulation**: Research indicates that the hypodopaminergic phenotype is prevalent in resistant depression, leading to a focus on dopamine receptor modulation, particularly the D3 receptor [3][4] - **Pramipexole**: A D3-preferring dopamine agonist showing promising efficacy in trials, with a meta-analysis indicating an average effect size of 0.64 across doses [4][6] - **Combination Therapy**: Chase Therapeutics developed a co-formulation of pramipexole and ondansetron to mitigate dose-related nausea and vomiting, allowing for faster and higher dosing [5][6] - **PAX-D Study Results**: A UK-based study showed a Cohen's d effect size of nearly 0.9 at 12 weeks, maintaining efficacy over 48 weeks, indicating strong potential for pramipexole in TRD [6][8] Study Design and Execution - **PAX-D Study Context**: Conducted within the NHS to encourage the use of pramipexole, utilizing a self-report measure (QUIDS) for depression [8][9] - **Retention and Rigor**: The study was well-run with robust results across multiple sites, addressing potential biases in patient selection [9][11] - **Phase 2b and Phase 3 Plans**: Phase 2b is set to start in the first half of 2027, with a sample size of 178 and a treatment duration of 8 weeks [18][19] Intellectual Property and Market Position - **IP Strategy**: Alto has secured intellectual property around the combination therapy and a modified release formulation, enhancing its market position [16][17] - **Non-obviousness Argument**: The combination of pramipexole and ondansetron was not previously explored, supporting the uniqueness of the approach [16] Cognitive Impairment in Schizophrenia - **CIAS Program**: Focuses on cognitive impairment in schizophrenia, a significant unmet need with no existing treatments [33][34] - **Mechanism of Action**: The drug is a PDE4 inhibitor targeting cyclic AMP, which is crucial for cognitive function [34][35] - **Study Design**: A crossover design assessing EEG changes as a primary outcome, with a focus on processing speed and memory [36][37] Execution and Risk Management - **In-house Operations**: Alto manages its trials internally, allowing for greater control and visibility compared to using a CRO [27][25] - **Patient Selection**: Implemented rigorous eligibility criteria to ensure a compliant patient population, reducing the risk of professional patients skewing results [24][25] Future Outlook - **Upcoming Data**: Anticipation for data from the CIAS study and ALTO-100 in the second half of the year [48][49] - **Cash Runway**: The company has sufficient cash to operate through 2029, indicating financial stability for ongoing projects [52] Conclusion - Alto Neuroscience is positioned to address significant gaps in the treatment of TRD and cognitive impairment in schizophrenia, with promising data and a robust pipeline supporting its strategic direction.